1052 related articles for article (PubMed ID: 19351790)
1. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
2. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth.
Hattori Y; Fukushima M; Maitani Y
Int J Oncol; 2007 Jun; 30(6):1427-39. PubMed ID: 17487363
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate.
Svechnikova I; Gray SG; Kundrotiene J; Ponthan F; Kogner P; Ekström TJ
Int J Oncol; 2003 Mar; 22(3):579-88. PubMed ID: 12579311
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis.
Vuyyuri SB; Hamstra DA; Khanna D; Hamilton CA; Markwart SM; Campbell KC; Sunkara P; Ross BD; Rehemtulla A
Clin Cancer Res; 2008 Apr; 14(7):2161-70. PubMed ID: 18381958
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of wound healing signaling as a potential therapeutic target for radiation-induced tissue damage.
Chung YL; Pui NN
Wound Repair Regen; 2015; 23(2):278-86. PubMed ID: 25682986
[TBL] [Abstract][Full Text] [Related]
7. Expression of survivin and XIAP for DMBA-induced hamster buccal pouch squamous cell carcinogenesis is associated with p53 accumulation.
Hsue SS; Chen YK; Lin LM
Oral Oncol; 2008 Jan; 44(1):43-9. PubMed ID: 17306609
[TBL] [Abstract][Full Text] [Related]
8. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of Zengshengping fractions on DMBA-induced buccal pouch carcinogenesis in hamsters.
Guan XB; Sun Z; Chen XX; Wu HR; Zhang XY
Chin Med J (Engl); 2012 Jan; 125(2):332-7. PubMed ID: 22340569
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression is regulated by an epigenetic mechanism for DMBA-induced hamster buccal-pouch squamous-cell carcinomas.
Chen YK; Hsue SS; Lin LM
Arch Oral Biol; 2005 Jun; 50(6):593-8. PubMed ID: 15848153
[TBL] [Abstract][Full Text] [Related]
12. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs.
Lea MA; Randolph VM; Hodge SK
Anticancer Res; 1999; 19(3A):1971-6. PubMed ID: 10470142
[TBL] [Abstract][Full Text] [Related]
13. Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Yang Y; Ge JP; Zhou ZT
J Oral Pathol Med; 2009 May; 38(5):455-62. PubMed ID: 19141066
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
15. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
de Ruijter AJ; Kemp S; Kramer G; Meinsma RJ; Kaufmann JO; Caron HN; van Kuilenburg AB
Biochem Pharmacol; 2004 Oct; 68(7):1279-88. PubMed ID: 15345317
[TBL] [Abstract][Full Text] [Related]
16. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
18. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells.
Appelskog IB; Ammerpohl O; Svechnikova IG; Lui WO; Almqvist PM; Ekström TJ
Int J Oncol; 2004 Jun; 24(6):1419-25. PubMed ID: 15138583
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
Kang J; Chen J; Shi Y; Jia J; Zhang Y
Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
